News & Analysis on Clinical Trial Services & Contract Research And Development
By Natalie Morrison
- Last updated on
Cunningham, whose 20-year career has most recently focused on respiratory drug development and drug delivery, is also executive chairman of PolyTherics, as well as non-executive director of Xention.
He joins the emerging pharmaceutical company – who are developing a portfolio of enhanced respiratory medicines enabled by its novel proprietary particle engineering technology – shortly after it received $17.6m (£11.4m) from its fund raising efforts.
Of his new appointment, Cunningham said: “Prosonix has the unique approach of developing respiratory medicines based on ‘smart’ particles whose fundamental properties are designed for delivery, using simple inhalation devices, to the parts of the respiratory system where they can elicit the optimal clinical effect.
”I am very much looking forward to working with the company during this exciting phase of its growth.”